CDKN1B and cancer: As many human tumors are characterized by low p27 expression [1], and small molecule CDK4,6 inhibitors are used in cancer therapy, pathway(s) lowering p27 levels upon sustained CDK inhibition might also become activated in human malignancies, contribute to chemoresistance and the outgrowth of more aggressive tumors upon relapse.